Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups - 02/08/23
Doi : 10.1016/S1470-2045(23)00286-3
David Pasquier, PhD MD a, c, ⁎ 
, Luc Bidaut, ProfPhD d, Daniela Elena Oprea-Lager, PhD MD e, Nandita M deSouza, ProfMD g, h, David Krug, MD i, Laurence Collette, PhD j, Wolfgang Kunz, ProfMD k, Yazid Belkacemi, ProfMD PhD l, m, Maria Grazia Bau, MD n, Caroline Caramella, MD o, Lioe-Fee De Geus-Oei, ProfMD PhD p, q, r, Alex De Caluwé, MD s, Christophe Deroose, ProfPhD MD u, Olivier Gheysens, ProfMD w, Ken Herrmann, ProfMD y, z, Isabelle Kindts, PhD MD ab, Michalis Kontos, ProfPhD ac, Sherko Kümmel, ProfPhD ad, ae, Barbro Linderholm, PhD MD af, ag, Egesta Lopci, PhD MD ah, Icro Meattini, MD ai, aj, Ann Smeets, ProfMD t, Orit Kaidar-Person, MD ak, al, Philip Poortmans, PhD MD am, an, Pelagia Tsoutsou, ProfPhD MD ao, Nawale Hajjaji, MD b, ap, Nicola Russell, PhD ar, Elżbieta Senkus, PhD MD as, Jean-Noël Talbot, ProfPhD MD at, Lale Umutlu, MD aa, Vincent Vandecaveye, ProfPhD MD v, Joost J C Verhoeff, PhD MD au, Willemien Menke-van der Houven van Oordt, MD PhD f, Helle D Zacho, ProfPhD MD av, Fatima Cardoso, MD aw, Laure Fournier, ProfPhD MD ax, Frederieke Van Duijnhoven, PhD MD aq, Frédéric E Lecouvet, ProfPhD MD x
, Luc Bidaut, ProfPhD d, Daniela Elena Oprea-Lager, PhD MD e, Nandita M deSouza, ProfMD g, h, David Krug, MD i, Laurence Collette, PhD j, Wolfgang Kunz, ProfMD k, Yazid Belkacemi, ProfMD PhD l, m, Maria Grazia Bau, MD n, Caroline Caramella, MD o, Lioe-Fee De Geus-Oei, ProfMD PhD p, q, r, Alex De Caluwé, MD s, Christophe Deroose, ProfPhD MD u, Olivier Gheysens, ProfMD w, Ken Herrmann, ProfMD y, z, Isabelle Kindts, PhD MD ab, Michalis Kontos, ProfPhD ac, Sherko Kümmel, ProfPhD ad, ae, Barbro Linderholm, PhD MD af, ag, Egesta Lopci, PhD MD ah, Icro Meattini, MD ai, aj, Ann Smeets, ProfMD t, Orit Kaidar-Person, MD ak, al, Philip Poortmans, PhD MD am, an, Pelagia Tsoutsou, ProfPhD MD ao, Nawale Hajjaji, MD b, ap, Nicola Russell, PhD ar, Elżbieta Senkus, PhD MD as, Jean-Noël Talbot, ProfPhD MD at, Lale Umutlu, MD aa, Vincent Vandecaveye, ProfPhD MD v, Joost J C Verhoeff, PhD MD au, Willemien Menke-van der Houven van Oordt, MD PhD f, Helle D Zacho, ProfPhD MD av, Fatima Cardoso, MD aw, Laure Fournier, ProfPhD MD ax, Frederieke Van Duijnhoven, PhD MD aq, Frédéric E Lecouvet, ProfPhD MD x a Academic Department of Radiation Oncology, Centre Oscar Lambret, Lille, France
b Medical Oncology Department, Centre Oscar Lambret, Lille, France
c University of Lille and CNRS, Centrale Lille, UMR 9189—CRIStAL, Lille, France
d College of Science, University of Lincoln, Lincoln, UK
e Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
f Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
g The Institute of Cancer Research, London, UK
h The Royal Marsden NHS Foundation Trust, Sutton, UK
i Department of Radiation Oncology, Universitaetsklinikum Schleswig-Holstein—Campus Kiel, Kiel, Germany
j Former European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium
k Department of Radiology, University Hospital, LMU Munich, Munich, Germany
l AP-HP, Radiation Oncology Department, Henri Mondor University Hospital, Créteil, France
m INSERM Unit 955 (-Bio), IMRB, University of Paris-Est (UPEC), Créteil, France
n Azienda Ospedaliera Città della Salute e della Scienza di Torino, Ospedale Sant’Anna, Turin, Italy
o Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint-Joseph, Paris, France
p Department of Radiology, Leiden University Medical Center, Leiden, Netherlands
q Biomedical Photonic Imaging Group, University of Twente, Enschede, Netherlands
r Department of Radiation Science and Technology, Delft University of Technology, Delft, Netherlands
s Radiotherapy Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
t Department of Surgical Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
u Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium
v Department of Radiology, University Hospitals Leuven, Leuven, Belgium
w Department of Nuclear Medicine, Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Institut du Cancer Roi Albert II, UCLouvain, Brussels, Belgium
x Department of Radiology, Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Institut du Cancer Roi Albert II, UCLouvain, Brussels, Belgium
y Department of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany
z German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany
aa Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany
ab Department of Radiation Oncology, Cancer Centre, General Hospital Groeninge, Kortrijk, Belgium
ac National and Kapodistrian University of Athens, Athens, Greece
ad Breast Unit, Kliniken Essen-Mitte, Essen, Germany
ae Charité – Universitätsmedizin Berlin, Department of Gynecology with Breast Center, Berlin, Germany
af Department of Oncolgy, Sahlgrenska University Hospital, Gothenburg, Sweden
ag Institution of Clinical Sciences, Department of Oncology, Sahlgrenska Academy at Gothenburg University, Gothenburg , Sweden
ah IRCCS Humanitas Research Hospital, Milan, Italy
ai Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy
aj Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
ak Oncology Institute, Sheba Tel Hashomer, Ramat Gan, Israel
al Tel-Aviv University, Tel-Aviv, Israel
am Department of Radiation Oncology, Iridium Netwerk, Antwerp, Belgium
an University of Antwerp, Antwerp, Belgium
ao Hôpitaux Universitaires de Genève, Site de Cluse-Roseraie, Geneva, Switzerland
ap Laboratoire Protéomique, Réponse Inflammatoire, et Spectrométrie De Masse (PRISM), Inserm U1192, Lille, France
aq Department of Surgical Oncology, The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands
ar Department of Radiotherapy, The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands
as Medical University of Gdańsk, Gdańsk, Poland
at Institut National des Sciences et Techniques Nucléaires, CEA-Saclay, Paris, France
au Department of Radiotherapy, University Medical Center Utrecht, Utrecht, Netherlands
av Department of Nuclear Medicine, Aalborg University Hospital, Aalborg, Denmark
aw Breast Unit, Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, Portugal
ax Université Paris Descartes Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
* Correspondence to: Assoc Prof David Pasquier, Academic Department of Radiation Oncology, Centre Oscar Lambret, Lille 59020, France Academic Department of Radiation Oncology Centre Oscar Lambret Lille 59020 France
Summary |
Breast cancer remains the most common cause of cancer death among women. Despite its considerable histological and molecular heterogeneity, those characteristics are not distinguished in most definitions of oligometastatic disease and clinical trials of oligometastatic breast cancer. After an exhaustive review of the literature covering all aspects of oligometastatic breast cancer, 35 experts from the European Organisation for Research and Treatment of Cancer Imaging and Breast Cancer Groups elaborated a Delphi questionnaire aimed at offering consensus recommendations, including oligometastatic breast cancer definition, optimal diagnostic pathways, and clinical trials required to evaluate the effect of diagnostic imaging strategies and metastasis-directed therapies. The main recommendations are the introduction of modern imaging methods in metastatic screening for an earlier diagnosis of oligometastatic breast cancer and the development of prospective trials also considering the histological and molecular complexity of breast cancer. Strategies for the randomisation of imaging methods and therapeutic approaches in different subsets of patients are also addressed.
Le texte complet de cet article est disponible en PDF.Plan
© 2023
Elsevier Ltd. Tous droits réservés.
Vol 24 - N° 8
P. e331-e343 - août 2023 Retour au numéro
Article précédent
- Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study
- Kristina Lång, Viktoria Josefsson, Anna-Maria Larsson, Stefan Larsson, Charlotte Högberg, Hanna Sartor, Solveig Hofvind, Ingvar Andersson, Aldana Rosso
- National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities
- Michelle M Kim, Minesh P Mehta, DeeDee K Smart, Patricia S Steeg, Julie A Hong, Michael G Espey, Pataje G Prasanna, Laura Crandon, Christine Hodgdon, Niki Kozak, Terri S Armstrong, Aki Morikawa, Nicole Willmarth, Kirk Tanner, Adrienne Boire, Melanie Hayden Gephart, Kim A Margolin, Jona Hattangadi-Gluth, Hussein Tawbi, Daniel M Trifiletti, Caroline Chung, Upal Basu-Roy, Robyn Burns, Isabella C Glitza Oliva, Ayal A Aizer, Carey K Anders, Joanne Davis, Manmeet S Ahluwalia, Veronica Chiang, Jing Li, Rupesh Kotecha, Silvia C Formenti, Benjamin M Ellingson, Vinai Gondi, Paul W Sperduto, Jill S Barnholtz-Sloan, Jordi Rodon, Eudocia Q Lee, Mustafa Khasraw, Debra Nana Yeboa, Priscilla K Brastianos, Evanthia Galanis, C Norman Coleman, Mansoor M Ahmed
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?